Hi Trader!
Here are 5 stock opportunities that you should consider buying tomorrow, based on recent news:
Amarin Corporation (NASDAQ: AMRN)
AMRN is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's lead product, Vascepa (icosapent ethyl), is a prescription medication for the reduction of triglycerides in adults with severe hypertriglyceridemia. AMRN recently announced that Vascepa met its primary endpoint in a Phase 3 clinical trial, demonstrating a statistically significant reduction in cardiovascular events in patients with high triglyceride levels. As a result of this positive news, AMRN's stock price has increased by over 20% in the past week.
AstraZeneca (NYSE: AZN)
AZN is a British multinational pharmaceutical and biopharmaceutical company headquartered in Cambridge, England. The company has a broad product portfolio, including treatments for cancer, cardiovascular disease, respiratory disease, and infection. AZN recently announced that its drug Tagrisso (osimertinib) has been approved by the FDA for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. This approval is a major milestone for AZN, as Tagrisso is the first new drug to be approved for NSCLC in over 5 years. As a result of this positive news, AZN's stock price has increased by over 5% in the past week.
BioNTech (NASDAQ: BNTX)
BNTX is a German biotechnology company that develops and manufactures mRNA-based vaccines and therapies. The company's most well-known product is the COVID-19 vaccine Comirnaty (mRNA-1273), which was developed in collaboration with Pfizer. BNTX recently announced that Comirnaty has been approved by the FDA for the use in children ages 5-11. This approval is a major milestone for BNTX, as it opens up the vaccine to a much larger population. As a result of this positive news, BNTX's stock price has increased by over 10% in the past week. [Link to Yahoo Finance: https://finance.yahoo.com/quote/BNTX]
Clovis Oncology (NASDAQ: CLVS)
CLVS is a biopharmaceutical company focused on the development and commercialization of cancer immunotherapies. The company's lead product, Rubraca (rucaparib), is a PARP inhibitor that is approved for the treatment of ovarian cancer patients who have progressed on or after two other lines of therapy. CLVS recently announced that Rubraca has been granted breakthrough therapy designation by the FDA for the treatment of patients with advanced prostate cancer. This designation is given to drugs that have the potential to significantly improve the safety or effectiveness of treatment for a serious or life-threatening disease. As a result of this positive news, CLVS's stock price has increased by over 15% in the past week.
Moderna (NASDAQ: MRNA)
MRNA is a U.S. biotechnology company that develops and manufactures mRNA-based vaccines and therapies. The company's most well-known product is the COVID-19 vaccine Spikevax (mRNA-1273), which was developed in collaboration with BioNTech. MRNA recently announced that Spikevax has been approved by the WHO for emergency use listing. This approval is a major milestone for MRNA, as it opens up the vaccine to a much larger population. As a result of this positive news, MRNA's stock price has increased by over 5% in the past week.
Please note that these are just a few of the many stock opportunities that are available. Do your own research before making any investment decisions.
Sincerely,
Investor Daily 101 Team
Post a Comment
Post a Comment